Gilead Sciences (GILD) Total Non-Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Non-Current Liabilities for 18 consecutive years, with $31.6 billion the latest figure, recorded in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $31.6 billion, down 12.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.6 billion (down 12.37% YoY), and the FY2025 annual result was $35.4 billion, down 8.98% from the prior year.
• Total Non-Current Liabilities was $31.6 billion for Q1 2026 at Gilead Sciences, down from $35.4 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $42.2 billion in Q1 2022 and troughed at $31.6 billion in Q1 2026.
• Average Total Non-Current Liabilities over 5 years is $37.5 billion, with a median of $37.4 billion recorded in 2024.
• Year-over-year, Total Non-Current Liabilities dropped 14.85% in 2024 and climbed 3.85% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $40.8 billion in 2022, then fell by 6.59% to $38.1 billion in 2023, then advanced by 2.16% to $38.9 billion in 2024, then declined by 8.98% to $35.4 billion in 2025, then slipped by 10.9% to $31.6 billion in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $31.6 billion in Q1 2026, $35.4 billion in Q4 2025, and $35.8 billion in Q3 2025.